These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. Stein AS, O'Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, Spielberger R, Somlo G, Margolin KA, Vora N, Lipsett J, Lee J, Niland J, Forman SJ. J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709 [Abstract] [Full Text] [Related]
28. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group]. Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G. Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():26-32. PubMed ID: 8692115 [Abstract] [Full Text] [Related]
29. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J. Bone Marrow Transplant; 1996 May 12; 17(5):685-9. PubMed ID: 8733682 [Abstract] [Full Text] [Related]
33. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, Thuret I, Bergeron C, Bordigoni P, Esperou-Bourdeau H, Perel Y, Vannier JP, Schaison G. Bone Marrow Transplant; 1996 Feb 12; 17(2):191-6. PubMed ID: 8640165 [Abstract] [Full Text] [Related]
37. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Rosenoff S. Support Care Cancer; 2004 Aug 12; 12(8):561-70. PubMed ID: 15160318 [Abstract] [Full Text] [Related]
38. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. Phillips GL, Shepherd JD, Barnett MJ, Lansdorp PM, Klingemann HG, Spinelli JJ, Nevill TJ, Chan KW, Reece DE. J Clin Oncol; 1991 Oct 12; 9(10):1880-8. PubMed ID: 1919638 [Abstract] [Full Text] [Related]